Menu
In a Cancer.net podcast, AONN+'s Program Director and Co-Founder Lillie Shockney, RN, BS, MAS discusses her presentation “The Value of Patient Navigators as Members of the Multidisciplinary Oncology Care Team” she made at the 2016 ASCO annual meeting. Come hear what she has to say on this significant topic.
The Navigation Metrics Team met recently to discuss the development of evidenced-based metrics within navigation related to the various components of care with the goal of rolling out these metrics and making them available so that every program can utilize them.
Medical oncologist Richard J. LoCicero, MD, believes navigators fill in the patient care blanks offering their value as coordinators, shoulders of support, and negotiators.
In the second installment of her series, AONN+ Program Director Lillie D. Shockney, RN, BS, MAS, talks about transforming patients' survivorship plans from unused medical documents into life plans that they will actively use to refer to for setting behavioral and lifestyle goals.
In the first of a 2-part series, AONN+ Program Director Lillie D. Shockney, RN, BS, MAS, addresses the importance of analyzing survivorship programs and some of the inherent challenges to do so, including a lack of clinical research and data implementation.
The scope of navigation has evolved from the Freeman model of community outreach and prevention to spanning the entire continuum of care for oncology patients. Navigators help individuals overcome barriers to care and navigate through the screening/diagnostic, treatment, survivorship, and end-of-life care continuum.
The case study for this discussion highlights the complexities of care coordination when patients arrive unprepared physically or mentally for the recommended medical treatments as determined by guidelines. It also shows how navigators can assemble needed care team players to efficiently guide the patient through prehabilitation and preparation for medical treatment.
Along with the diagnosis of breast cancer comes many decisions regarding treatment options. Oncotype DX, a genomic/gene expression assay, provides quantitative assessment of chemotherapy benefit and risk of distant recurrence in early-stage estrogen receptor–positive (ER+), HER2/neu-negative breast cancer to assist in developing individualized treatment plans.
The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to introduce the Oncology Patient Navigator–Certified Generalist (OPN-CG) credential. This credential is important for anyone who provides cancer navigation services and is not a nurse. For nurses, AONN+ is providing the Oncology Nurse Navigator – Certified Generalist credential (ONN-CG).
As navigators you are well aware of the financial burden a diagnosis of cancer can have on a patient and his or her family. Deductibles, copayments, missed time from work, and uncovered ancillary care by their insurance company all add up to huge out-of-pocket costs. Did you know that cancer costs continue for years even as a cancer survivor?
Page 2 of 9
Results 11 - 20 of 84

Thank You to Our Corporate Sponsors and Alliance Partners!

  • Major Corporate Sponsor

    Major Corporate Sponsor

  • Patron Corporate Sponsor

    Patron Corporate Sponsor

  • Patron Corporate Sponsor

    Patron Corporate Sponsor

  • Industry Relations Council Member

    Industry Relations Council Member

  • Patron Corporate Sponsor

    Patron Corporate Sponsor

  • Patron Corporate Sponsor

    Patron Corporate Sponsor

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • Industry Relations Council Member

    Industry Relations Council Member

  • National Alliance Partner

    National Alliance Partner

  • National Alliance Partner

    National Alliance Partner